Navigation Links
Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
Date:11/2/2012

to $1.2 to $1.3 billion due to increased investment in working capital associated with the growth in emerging markets, asset deals which require an investment in working capital post-closing, and plant consolidations including the closing of the Bourdon facility in Canada and the exiting of a legacy Valeant contract manufacturer in Puerto Rico.  Valeant is maintaining prior guidance of total revenue in the range of $3.4 to $3.6 billion.  

Conference Call and Webcast InformationThe Company will host a conference call and a live Internet webcast along with a slide presentation today at 8:00 a.m. ET (5:00 a.m. PT), November 2, 2012 to discuss its third quarter financial results for 2012. The dial-in number to participate on this call is (877) 281-0402, confirmation code 39252322. International callers should dial (631) 813-4869, confirmation code 39252322. A replay will be available approximately two hours following the conclusion of the conference call through November 9, 2012 and can be accessed by dialing (855) 859-2056, or (404) 537-3406, confirmation code 39252322. The live webcast of the conference call may be accessed through the investor relations section of the Company's corporate website at www.valeant.com.

About ValeantValeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking StatementsThis press release may contain forward-looking statements, including, but not limited to, statements regarding the closing of the Medicis acquisitions, the approval of efinaconazole (IDP-108), future results and performance and financial guidance, including expected revenue and adjusted cas
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Calif. , June 19, 2013  Omnicell, ... provider of medication and supply management solutions and ... it was named the number one overall pharmacy ... & Infrastructure Report. KLAS, a leading independent healthcare ... automation equipment vendors in its annual rankings. Omnicell ...
(Date:6/19/2013)... Pharma IQ is pleased to announce ... of the results from an industry survey conducted earlier this ... that CROs would be an area of active investment in ... 6 or more clinical trials in the BRIC region. The ... USA Summit explores the latest trends, challenges ...
(Date:6/19/2013)... 19, 2013  It may seem like an odd pairing: ... cancer. But these were two of the most talked about ... Annual Meeting & Expo that just convened in ... focus by some of the top internal medicine experts in ... new research that can not only save lives, but help ...
Breaking Medicine Technology:Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4
... ,Automation continues to gain importance in modern ... consolidation, rising demands from clinicians for rapid ... licensed medical technologists. Ultimately, the laboratories that ... to meet these modern demands. , ,Within ...
... Content Editor Medcompare.com ,According to a November, 2005 ... HIV/AIDS) and the World Health Organization, the number of people ... million people in 2005, with over 3 million deaths caused ... Disease Control shows that over one million people in the ...
Cached Medicine Technology:Optimizing Quality Control Data Management 2Optimizing Quality Control Data Management 3Optimizing Quality Control Data Management 4Optimizing Quality Control Data Management 5Rapid HIV Testing Increases Possibility of Treatment 2Rapid HIV Testing Increases Possibility of Treatment 3
(Date:6/19/2013)... led by researchers at The University of Texas MD ... show remarkable promise for the treatment of relapsed or ... interim findings of the 18-center Phase 2 study were ... Medicine . Previous interim findings were presented in December ... Meeting and Exposition. , Unprecedented results, fewer ...
(Date:6/19/2013)... half as many emergency department visits if their primary ... more days a week, according to new research from ... Johns Hopkins University. , The new study was published ... and will be presented at the AcademyHealth Annual ... in understanding where primary care practices and medical home ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on at ... take two, Mayo Clinic researchers say. Antibiotics, antidepressants ... study found. Twenty percent of patients are on ... findings, published online in the journal Mayo ... and video of Dr. Jennifer St. Sauver talking ...
(Date:6/19/2013)... 19, 2013 North Carolina-based life ... changes to advance development of its technologies. , ... support the advanced development of our product candidates ... the Company’s management structure and engaged industry leaders ... announced that Michael Galiger will serve as Vice ...
(Date:6/19/2013)... Brightree LLC , the leading provider of ... post-acute care industry, has been ranked for the first time ... 100 (HCI 100) list. This prestigious list features the ... of revenue during the last fiscal year. Since 2005, Brightree’s ... and the company has built its organization to more than ...
Breaking Medicine News(10 mins):Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3
... Roche and Memory Pharmaceuticals (Nasdaq: MEMY ... a definitive merger agreement for Roche to acquire all ... transaction for an aggregate price of approximately USD 50 ... Memory Pharmaceuticals develops innovative drug candidates for the treatment ...
... 25 Pennsylvania will benefit a potential $16 million ... Botvin LifeSkills Training program, a drug abuse ... released by the Prevention Research Center at Pennsylvania ... of this highly effective program yields a return on ...
... DETROIT, Nov. 24 Caraco Pharmaceutical,Laboratories, Ltd. (NYSE Alternext ... response to the FDA warning letter that was received ... requested a response from Caraco,within 15 business days, ending ... As previously disclosed, the warning letter was issued ...
... , , MONDAY, Nov. 24 (HealthDay News) -- A drug ... and caused fewer side effects than the widely-used migraine ... drug maker Merck & Co. , Zolmitriptan and other ... side effects, including dizziness, tingling and numbness of the ...
... University of California, San Diego (UCSD) and the Moores ... novel drug target for an often difficult-to-treat form of ... pattern of a specific family of enzymes in patients ... of adult leukemia. , Paul Insel, M.D., professor ...
... announced on Friday that Garvan endocrinologist and PhD student, Dr ... the AAAS Science "Dance your PhD" contest. See ... Science magazine challenged researchers around the world to interpret ... share it with the world on YouTube by mid-November. ...
Cached Medicine News:Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 2Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 3Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 4Health News:Drug Abuse and Violence Prevention Program Generates $16 Million in Potential Savings 2Health News:Drug Abuse and Violence Prevention Program Generates $16 Million in Potential Savings 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter 2Health News:New Migraine Drug Shows Promise 2Health News:UCSD researchers identify potential new drug target for chronic leukemia 2Health News:Ph.D. student Sue Lynn Lau dances her way to Chicago 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: